Henry H. Balfour, Jr., M.D.

Contact Information Phone: 612-626-5670 Fax: 612-625-5468 Email: balfo001@umn.edu Address: MMC 437 Mayo 8437 420 Delaware Minneapolis, MN 55455

Professor

Medical Director, Clinical Virology Laboratory

Dr. Balfour’s primary staff appointment is at University of Minnesota Medical Center, Fairview, where he instructs residents in the virology section of the microbiology rotation.

Research

• Principal Investigator, University of Minnesota AIDS Clinical Trials Unit (NIH)
• Co-investigator, Minnesota AIDS Clinical Trials Unit Advanced Technology HIV laboratory
• Co-investigator, Great Lakes Center for AIDS Research (AFAR, an NIH-sponsored consortium with Northwestern University, University of Wisconsin and University of Michigan)
• Director, International Center for Antiviral Research and Epidemiology
• Project Director, collaborative research on concentration-controlled antiretroviral therapy for the management of HIV disease

Educational Background

• Columbia University (1966), M.D.
• University of Minnesota (1968), Internship (Pediatrics)
• Columbia Babies Hospital (1969), Residency (Pediatrics)
• University of Minnesota (1972), Fellowship (Pediatric Infectious Disease)

Board Certification

Pediatrics

Professional Memberships

• Editorial Board of the International Journal of Antimicrobial Agents
• Scientific Advisory Board of the Varicella-Zoster Virus Research Foundation
• Infection Control Committee
• Advisory Board for Emerging Pathogens Program of the Minnesota Department of Health

Publications

Dr. Balfour has written extensively on a number of virology topics, including antiviral combination drug therapy protocols for HIV. He is an ad hoc reviewer for seven scientific journals.

• Weller DR, Balfour HH Jr, Vezina HE. Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. Biomed Chromatogr. 2009 Aug;23(8):822-7.
• Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007 May;39(1):16-21.
• Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):369-73.
• Vezina HE, Henry K, Ravindran GD, Kurpad AV, Raj TD, Fox K, Weller D, Brundage RC, Cavert W, Balfour HH Jr. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):131-6.
• Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb CH, Cavert W, Wang DH, Brundage RC. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005 Nov 1;192(9):1505-12.

For a complete listing of Dr. Balfour's publications, please search PubMed.
 

Invited Lectures

• May 6-11, 2005, Clearwater Beach, FL. Pan American Society for Clinical Virology, attended the scientific sessions and presented 4 posters
• July 19, 2005, Minneapolis, MN Dept of Laboratory Medicine and Pathology Case Conference. Presented a talk: Resistant CMV infection in a bone marrow transplant patient
• Sept 11, 2005, Minneapolis, MNACTU Community Advisory Board. Presented a talk: HIV superinfection
• Oct 6-8, 2005, San Francisco. Infectious Diseases Society of America - Attended the scientific sessions and presented a poster
• Oct 27, 2005, Minneapolis, MN. North American Collegiate Health Conference. Invited talk: Infectious mononucleosis: can it be treated after all?
• Nov 28-Dec 1, 2005, Baltimore, MDAIDS Clinical Trials Group (ACTG) Investigators Meeting. Attended the scientific sessions and represented MN as the Principal Investigator of the MN ACTU
• Dec 16-19, 2005, Washington, DC. ICAAC - This is the major annual U.S. Infectious Diseases meeting, which I attended and presented peer-reviewed research at an oral session
• March 9, 2006, Minneapolis, MNACTU Community Advisory Board. Presented a talk: HIV superinfection
• March 20-23, 2006, San Diego, CAAIDS Clinical Trials Group (ACTG) Leadership Retreat. Attended the scientific sessions and represented MN as the Principal Investigator of the MN ACTU
• April 3, 2006, Minneapolis, MN Bone Marrow Transplant Conference. Introduction of the qCMV assay and comparison with the pp65 antigenemia test
• April 5, 2006, Minneapolis, MN Department of Surgery Transplant Conference. Clinical application of the qCMV and qEBV assays
• April 29-May 3, 2006, Clearwater Beach, FL Pan American Society for Clinical Virology. Attended the scientific sessions and presented 2 posters
• June 1-3, 2006, Chicago, ILACLPSCo-author of a slide presentation by Carol Holman: EBV shedding patterns in acute and chronic infection
• June 21, 2006, Minneapolis, MN Department of Surgery Transplant Conference. Presented a talk: EBV infections: A Minnesota Odyssey
• Aug 1, 2006, Minneapolis, MN Dept of Laboratory Medicine and Pathology Case Conference. Presented a talk: Clinical trial design: discussion of planned research on primary EBV infections in University of Minnesota students
• Sept 27, 2006, Minneapolis, MN Department of Surgery Transplant Conference. Presented a talk: The role of viruses in posttransplant morbidity
• Oct 13-15, 2006, Toronto Canada Infectious Diseases Society of America. Attended the scientific sessions and presented a poster: A real-time TaqMan PCR assay for quantitation of CMV and comparison with the pp65 antigenemia test
• Nov 15, 2006, Minneapolis, MN. Department of Pediatrics Grand Rounds Gave Grand Rounds: EBV infections: A Minnesota Odyssey
• Dec 13, 2006, Minneapolis, MN ACTU Community Advisory Board. Presented awards to the members and officers
• Feb 9, 2007, Burnsville, MN Grand Rounds, Fairview Ridges. Presented a talk: Infectious mononucleosis: A Minnesota odyssey
• Feb 21, 2007, Minneapolis, MN Department of Surgery Transplant Conference. Presented a talk: Viral infections and posttransplant morbidity
• April 28-May 2, 2007, Clearwater Beach, FL. Pan American Society for Clinical Virology. Attended the scientific sessions and presented and received the PASCV Clinical Virology Award for 2007
• July 31, 2007, Minneapolis, MN Dept of Laboratory Medicine and Pathology Case Conference. Presented a talk: Surprising developments in the war against EBV
• Aug 31, 2007, Minneapolis, MN University of Minnesota Health Advocates Training Session. Discussed our ongoing study: Risk factors for the severity of infectious mononucleosis due to primary Epstein-Barr virus infection in university students: (Mono 5)
• Oct 4-7, 2007, San Diego. Infectious Diseases Society of America. Attended the scientific sessions and presented a poster: Clinical, viral and antibody kinetics during infectious mononucleosis.
• Oct 11, 2007, Minneapolis, MN Boynton Health Service Grand Rounds. Presented a talk: Surprising developments in the war against EBV
• Nov 9, 2007, Minneapolis, MN. CME Conference on Emerging Infections. Presented a talk: Update on antiviral drugs

Presentations

• Balfour HH Jr. HIV-1 fitness and disease progression: the missing piece of the puzzle? Presented at the 19th Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, April 29, 2003.
• Lelonek MM, Giesbrecht JE, Weller D, Fietzer CM, Cavert W, Balfour HH Jr. Anti-HIV activity of plasma during combination antiretroviral therapy. Presented at the Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists, Tucson AZ, June 6, 2003.
• Cavert W, Webb C, Hokanson K, Balfour HH Jr. Competitive whole virus fitness assay using GFP reporter virus for analysis of HIV-1 isolates free of selective drug pressure. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 15, 2003. Abstract H807.
• Balfour HH Jr, Holman CJ, Giesbrecht JE, Hokanson K, White DR, Webb C, Schmeling DO, Wang DH, Lelonek M, Cavert W. Quantitative Epstein-Barr virus (EBV) shedding during acute infectious mononucleosis: the kissing disease confirmed. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 16, 2003. Abstract V1292.
• Balfour HH Jr. Resistance testing for HSV, VZV, CMV, HBV, HIV. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL, September 17, 2003. Abstract 2076.
• Balfour HH Jr. Molecular methods for the detection and monitoring of EBV-associated diseases. Presented at the 20th Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, April 24, 2004.
• Hokanson K, Holman CJ, Lelonek M, Webb C-H, Wang DH, White DR, Schacherer R, Schmeling DO, Giesbrecht JE, Brundage RC, Cavert W, Balfour HH Jr. A prospective quantitative study of the clinical and virologic events in acute infectious mononucleosis. Presented at the 20th Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, April 27, 2004. Abstract T37.
• Stratton C, Balfour HH Jr. Evaluation of two rapid antibody kits for determining risk of acquisition of HIV in health care workers exposed to body fluids. Presented at the 20th Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, April 25, 2004. Abstract S17.
• Holman CJ, Gulbahce EH, McKeon DM, van Burik J, Balfour HH Jr, Pambuccian SE. BK virus infection in asymptomatic immunosuppressed patients: comparison of urine cytology and semi-quantitative PCR. Presented at the Annual Meeting of the College of American Pathologists, Phoenix AZ, September 18-21, 2004.
• Vezina HE, Henry K, Ravindran G, Kurpad A, Raj T, Fox K, Weller D, Brundage R, Bromander R, Cavert W, Balfour HH Jr. An international bioequivalence study of generic and brand formulations of nevirapine, zidovudine, and lamivudine. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston MA, Feb 22-25, 2005. [abstract 669] In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
• Hokanson KM, Lelonek MM, Lynch MA, Balfour HH Jr. Performance of the DiaSorin and Diamedix enzyme immunoassays for detection of Epstein-Barr virus (EBV) antibodies during primary infectious mononucleosis. Presented at the 21st Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 8-11, 2005. Abstract TA18.
• Romain CA, Joseph EM, Libby KJ, Hokanson KM, Holman CJ, Webb C-H, Schmeling DO, Balfour HH Jr. Monitoring the quantity of Epstein-Barr virus (EBV) in whole blood (WB) samples of patients at a university medical center. Presented at the 21st Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 8-11, 2005. Abstract TA22.
• Webb C-H, Hokanson KM, Balfour HH Jr. Stability in the sequence variation of the Epstein-Barr virus (EBV) LMP1 gene in individual patients enhances its potential to be an epidemiologic tool. Presented at the 21st Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 8-11, 2005. Abstract TA23.
• Hokanson KM, Webb C-H, Schmeling DO, Brundage RC, Balfour HH Jr. A prospective study of Epstein-Barr virus (EBV) infection in healthy adults. Presented at the 21st Annual Meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 8-11, 2005. Abstract TA25.
• van Burik J, Holman CJ, Romain C, Balfour HH Jr. BK virus (BKV) infection monitored by real-time TaqMan blood and urine polymerase chain reaction (PCR). Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 8, 2005. Abstract 722.
• Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Brundage RC. A controlled trial of valacyclovir in infectious mononucleosis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 18, 2005. Abstract V1392.
• Romain CA, Balfour HH Jr. Cytomegalovirus quantitation: comparison of a real-time TaqMan PCR assay with pp65 antigenemia and evaluation of viral load in whole blood, plasma, and peripheral blood leukocytes. Presented at the 22nd annual meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 1, 2006. Abstract M38.
• Hokanson KM, Hayden RT, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Valsamakis A, Balfour HH Jr for the U.S. EBV Working Group. A multicenter comparison of different real-time PCR assays for the quantitative detection of Epstein-Barr virus (EBV). Presented at the 22nd annual meeting of the Pan American Society for Clinical Virology, Clearwater Beach FL, May 1, 2006. Abstract M49.
• Holman CJ, Webb C-H, Hokanson KM, Schmeling DO, Cook ME, Romain CA, Balfour HH Jr. Epstein-Barr virus (EBV) shedding patterns in acute and chronic infection. Presented at the Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists, Chicago, IL, June 2, 2006. In: Am J Clin Pathol 2006; 126:461-2. Abstract 25.
• Snydman DR, Barefoot L, Ruthazer R, Weinberg, A, Paya C, Balfour HH Jr, Burke RL, Duliege A-M. Analysis of the cytomegalovirus (CMV) gB vaccine with MF 59 adjuvant (CMVgB) in CMV seronegative patients with renal failure on a transplant list. Presented at the 14th International Symposium on Infections in the Immunocompromised Host, Crans-Montana, Switzerland, July 3, 2006.
• Romain CA, Balfour HH Jr. A real-time TaqMan PCR assay for quantitation of cytomegalovirus (CMV) in whole blood, plasma and peripheral blood leukocytes (PBL) and comparison with the pp65 antigenemia test. Presented at the 44th annual meeting of the Infectious Diseases Society of America, Toronto, Canada, October 14, 2006. Abstract 870.
• Holman CJ, Webb C-H, Romain CA, Balfour HH Jr. A method for evaluating susceptibility of EBV to antiviral drugs. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 18, 2007. Abstract V1381.
• Balfour HH Jr, Schmeling DO, Vezina HE, Fietzer CM, Brundage RC. Clinical, viral and antibody kinetics during infectious mononucleosis. Presented at the 45th annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 6, 2007. Abstract 742.